• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stifel initiated coverage on Vigil Neuroscience with a new price target

    2/1/22 7:54:06 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIGL alert in real time by email
    Stifel initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $24.00
    Get the next $VIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIGL

    DatePrice TargetRatingAnalyst
    5/28/2025$8.00Buy → Hold
    Stifel
    12/4/2024Outperform
    William Blair
    12/19/2023$13.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    10/18/2023$23.00Mkt Outperform
    JMP Securities
    3/31/2023$15.00Buy
    Mizuho
    9/16/2022$19.00Outperform
    Wedbush
    8/29/2022$24.00Buy
    H.C. Wainwright
    2/1/2022$17.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $VIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vigil Neuroscience downgraded by Stifel with a new price target

      Stifel downgraded Vigil Neuroscience from Buy to Hold and set a new price target of $8.00

      5/28/25 8:11:47 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Vigil Neuroscience

      William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform

      12/4/24 7:51:48 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

      12/19/23 7:39:43 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Budd Haeberlein Samantha L. bought $20,520 worth of shares (12,000 units at $1.71) (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:44:11 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,400 worth of shares (5,000 units at $1.68), increasing direct ownership by 2% to 222,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:42:45 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,350 worth of Common Stock (5,000 units at $1.67), increasing direct ownership by 2% to 217,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/18/24 5:51:48 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care